 |
Management
The management team is a collection of experienced pharmaceutical executives,
proven entrepreneurs, and world class scientists. Having worked together in the
past, they have recently come together to build Yaupon Therapeutics into a successful enterprise.
Robert Alonso, President & CEO is a seasoned executive with 15 years of domestic and
international pharmaceutical experience in licensing, drug development and marketing.
He has held management positions for large multi-nationals such as Merck and Hofmann
La Roche as well as biotech start-ups with Layton Bioscience. Mr. Alonso has run a $200
million infectious disease franchise and he has closed over 15 licensing deals. Mr. Alonso
has an MBA from F.W. Olin Graduate School at Babson College.
Peter Crooks, Ph.D., Chief Scientific Officer,
is an internationally recognized expert in medicinal chemistry with extensive experience in drug
discovery and development. He is full professor and an Endowed Chair in the Division of Pharmaceutical
Sciences, University of Kentucky and works part-time with Yaupon. Dr. Crooks has authored over 500 papers
and holds more than 70 patents in the area of drug discovery. He is the recipient of numerous awards. Dr. Crooks
received his B.S., M.S., and Ph.D. degrees from the University of Manchester, U.K.
Thomas P. Hess, CPA, Senior Vice President, Finance, and Chief Financial Officer,
is a seasoned financial executive with 20 years of domestic and international experience. Prior to joining Yaupon Therapeutics,
Mr. Hess was the Vice President, Finance and Chief Financial Officer of Adolor Corporation from 2005 to 2008 where his
responsibilities included investor relations, SEC reporting and cash management. From 2003 until joining Adolor Corporation,
Mr. Hess was Corporate Controller of Vicuron Pharmaceuticals, Inc, a biopharmaceutical company that was acquired by Pfizer I
nc. in 2005 for $1.9 billion. From 2000 until 2003, Mr. Hess was Controller of Innovative Solutions and Support, Inc.,
a manufacturer of high tech avionics equipment. Prior to joining Innovative Solutions and Support, Inc., Mr. Hess was with
KPMG LLP for ten years in various positions, including as a senior manager. Mr. Hess has a Bachelor of Science in accounting
from Pennsylvania State University and a Masters of Business Administration in Finance from the University of Pittsburgh.
Mark S. Kleven, Ph.D., Vice President, Scientific Operations,
was previously the Head of Behavioral Pharmacology, Neurobiology II at the Centre de Recherche Pierre Fabre in preclinical
research directed toward discovery of drug candidates for CNS diseases. During the twelve years at Pierre Fabre he was involved
in pivotal studies identifying six candidates for development. He has authored over 150 papers and abstracts. Prior to joining
Pierre Fabre, Dr. Kleven spent seven years in various roles in the Department of Pharmacology and Physiological Sciences at the
University of Chicago. Dr Kleven received his Ph.D. in Pharmacology in 1986 from the University of Minnesota.
Barry Walker, M.D., F.A.C.P., Executive Vice President, Regulatory and Clinical Development, i
is adjunct professor of medicine at the University of Pennsylvania and serves part-time at Yaupon. Dr. Walker has 25 years of management
experience in the pharmaceutical and biotechnology industries and was Senior Vice President for Clinical Research and Development at Wyeth-Ayerst.
He has successfully guided 25 products through NDA approval and has authored over 125 publications. Dr. Walker received his B.A. from Yale and his
M.D. from Columbia University.
Office Address:
Radnor, PA
259 North Radnor-Chester Road, Suite 205
Radnor, PA 19087
P 610-975-9290
F 610-975-9012
For additional information about Yaupon Therapeutics, please email us at info@yaupontherapeutics.com |
 |
 h |
 |
|
